CJC-1295 with DAC 5mg

CJC-1295 with DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH) belonging to the class of growth hormone secretagogues (release-stimulating molecules). It differs from the standard form by a coupled Drug Affinity Complex (DAC), a chemical group that binds covalently to plasma albumin, thereby significantly prolonging the circulation time of the molecule. Within scientific research, the compound is studied as a model compound around the GHRH receptor and the GH/IGF-1 signaling axis. Intended exclusively for laboratory and research purposes.

What is the CJC-1295 with DAC?

CJC-1295 with DAC is constructed around the first 29 amino acids of human GHRH — the same peptide backbone as Mod GRF 1-29 — featuring several amino acid substitutions that enhance molecular stability. A lysine-maleimidopropionyl group is attached to this backbone: the actual Drug Affinity Complex. The compound was originally described by ConjuChem Biotechnologies and is also referred to as DAC:GRF in the literature. Structurally, it is therefore a GHRH(1-29) analog with an albumin-binding fragment, making it an interesting model compound for research into long-acting peptide chemistry.

In contrast to the short, pulsatile action of unmodified GHRH fragments, CJC-1295 with DAC is designed to remain present in solution for an extended period. This makes the compound suitable as a reference model when researchers wish to study the behavior of albumin-bound peptides relative to their short-acting counterparts.

The Drug Affinity Complex (DAC) under investigation

The distinguishing feature of this variant is the Drug Affinity Complex. Once the peptide is brought into solution, the maleimidopropionyl group forms a covalent bond with a free thiol group on circulating albumin. Because the molecule is thus coupled to a large carrier protein, it is degraded less rapidly by proteases and cleared more slowly. In research models, this shifts the effective half-life from the order of minutes to several days. For researchers, this mechanism is relevant as a study model for half-life-extending strategies and for comparing continuous versus pulsatile receptor exposure.

Research areas

• GHRH receptor binding and downstream cAMP signal transduction in vitro
• Pharmacokinetics of albumin-bound peptides and mechanisms of half-life prolongation
• Comparative study of continuous versus pulsatile activation of the GHRH receptor
• Modeling of the GH/IGF-1 signaling axis in preclinical systems
• Proteolytic and conformational stability of modified GHRH analogues
• Comparative receptor studies alongside ghrelin receptor agonists (GHRP class)

CJC-1295 with DAC compared to related connections

Within the group of growth hormone secretagogues, there are multiple structurally related model compounds that are often studied alongside each other. The direct counterpart is CJC-1295 without DAC (Mod GRF 1-29), which shares the same GHRH backbone but lacks the albumin-binding complex and therefore has a much shorter circulation time. Tesamorelin is another stabilized GHRH analog, based on the complete GHRH(1-44) fragment with an N-terminal acyl group, while Sermorelin is precisely one of the shortest GHRH analogs and often serves as a reference. A separate mechanistic class are the ghrelin receptor agonists such as Ipamorelin, which act on the GH axis via a different signal path and are regularly modeled together with GHRH analogues in comparative research.

Specifications

Shape, handling and storage

The compound is offered as a single vial containing 5 mg of freeze-dried powder (lyophilisate). The freeze-dried powder remains stable for a long time when stored in a cool, dark, and moisture-free environment. For use in a research setup, the lyophilisate is reconstituted with a suitable solvent, such as bacteriostatic water; work sterilely and allow the solvent to run gently down the wall of the vial rather than directly onto the powder. After reconstitution, the solution is stored refrigerated (2–8 °C) and protected from light. Repeated freezing and thawing are generally avoided in research protocols to preserve the conformational integrity of the peptide.

Purity and lab results

CJC-1295 with DAC is offered with a controlled purity of ≥ 99%, determined by HPLC. The current analysis certificates and purity data of our compounds can be consulted on the lab results page.

Frequently Asked Questions

What is the difference between the CJC-1295 with and without a DAC?
Both share the same GHRH(1-29) backbone. The variant with DAC carries an extra albumin-binding complex, causing the molecule to remain in circulation much longer in research models than the form without DAC.

What does the abbreviation DAC stand for?
DAC stands for Drug Affinity Complex: a chemical group that binds covalently to plasma albumin and thereby delays the clearance of the peptide.

In what form is the connection supplied?
As a freeze-dried powder (lyophilisate) of 5 mg per vial, which is reconstituted before research use.

How is it stored?
The freeze-dried powder should be kept cool, dark, and dry; after reconstitution, refrigerated at 2–8 °C and protected from light.

Want to know more? Read our guide: HGH peptides explained: GHRH analogs, GHRPs, and the difference from real growth hormone.

Intended exclusively for laboratory and research purposes. Not for human or animal consumption, or for medical, diagnostic, therapeutic, or cosmetic use. The buyer is 18+ and confirms the research context. Not a medicine.